As of November 6, 2026, Vor Biopharma Inc. is a publicly traded company (Nasdaq: VOR). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 19.9%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Fidelity (FMR) (10.7%), Venrock Healthcare Capital Partners III, L.P. (9.9%), Verve Capital Limited (6.3%) (Schedule 13D/A, July 21, 2026).
Is this your company?
About to sign with, pay or invest in Vor Biopharma Inc.? See the free Snapshot first.
Free to see. No signup.
Is Vor Biopharma Inc. a real, registered company?
- Vor Biopharma Inc. files with the SEC under CIK 1817229 (its SEC filings).
- Its shares are listed under the ticker VOR on Nasdaq (SEC company record).
- business address in Boston, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under VOR BIOPHARMA INC in our court records and SEC 8-K records (as of 2026-11-06).
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Fidelity (FMR) (filed 2026-11-05).
Who are Vor Biopharma Inc.'s owners and officers?
Vor Biopharma Inc.: business address in Boston, Massachusetts; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-05).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-05 | Fmr LLC | 10.7% |
| Schedule 13G/A, 2026-08-14 | Frazier Life Sciences Public Fund, L.P. | 4.2% |
| Schedule 13G/A, 2026-08-14 | Venrock Healthcare Capital Partners Iii, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-13 | Verve Capital Limited | 6.3% |
| Schedule 13G/A, 2026-08-07 | Fmr LLC | 12% |
| Schedule 13G, 2026-08-06 | Fmr LLC | 9.1% |
| Schedule 13G, 2026-07-30 | Blackrock, Inc. | 5.7% |
| Schedule 13D/A, 2026-07-21 | Ra Capital Management, L.P. | 19.9% |
| Schedule 13G/A, 2026-05-15 | Verve Capital Limited | 9.3% |
| Schedule 13G/A, 2026-05-15 | Venrock Healthcare Capital Partners Iii, L.P. | 9.9% |
| Schedule 13G/A, 2026-05-06 | Fmr LLC | 3.2% |
| Schedule 13G/A, 2026-05-06 | Qiming Venture Partners Viii-Hc, L.P. | 2% |
Questions about who owns Vor Biopharma Inc.
Who owns Vor Biopharma Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Vor Biopharma Inc.: Ra Capital Management, L.P. (19.9%, Schedule 13D/A, filed 2026-07-21), Fmr LLC (10.7%, Schedule 13G/A, filed 2026-11-05), Venrock Healthcare Capital Partners Iii, L.P. (9.9%, Schedule 13G/A, filed 2026-08-14), Verve Capital Limited (6.3%, Schedule 13G/A, filed 2026-08-13) and Blackrock, Inc. (5.7%, Schedule 13G, filed 2026-07-30).
Who are the largest shareholders of Vor Biopharma Inc.?
By the share each holder's latest filing reports, the largest holders of Vor Biopharma Inc. on this page are Ra Capital Management, L.P. (19.9%), Fmr LLC (10.7%) and Venrock Healthcare Capital Partners Iii, L.P. (9.9%).
When did Ra Capital Management, L.P. buy into Vor Biopharma Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2026-07-21, reporting 19.9%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Vor Biopharma Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Vor Biopharma Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Vor Biopharma Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
15 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Which insiders own Vor Biopharma Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- TCG Crossover Fund II, L.P., a 10% owner: 2,836,539 shares (4.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2026-04-01).
- TCG Crossover GP II, LLC, a 10% owner: 2,836,539 shares (4.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2026-04-01).
- TCG Crossover Fund III, L.P., a 10% owner: 2,836,539 shares (4.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2026-04-01).
- TCG Crossover GP III, LLC, a 10% owner: 2,836,539 shares (4.6% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 3, 2026-04-01).
- RA Capital Nexus Fund, L.P., a director: 1,401,226 shares (2.3% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2025-10-22).
Shares outstanding: 61,434,344 as of 2026-10-26, from the company's latest SEC cover page.
How much has Vor Biopharma Inc. raised?
No fundraising or offering filing from Vor Biopharma Inc. is on file with us.
Keep reading
More on Vor Biopharma Inc. and the records around it.
Vor Biopharma Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
Companies that share a holder
- 5AM Ventures VI, L.P. also filed stake reports on 2 other companies: CAMP4 THERAPEUTICS CORPORATION (Aug 2026), ARTIVA BIOTHERAPEUTICS, INC. (Aug 2026)
- ForGrowth III PA B.V. also filed stake reports on 4 other companies: Aura Biosciences, Inc. (Oct 2026), Crescent Biopharma, Inc. (Dec 2025), Astria Therapeutics, Inc. (Nov 2025)
- Great Point Partners, LLC also filed stake reports on 14 other companies: LeonaBio, Inc. (Nov 2026), Research Alliance Corporation III (Sep 2026), JATT III Acquisition Corp (Sep 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/vor-biopharma